Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

Core Viewpoint - Eyenovia, Inc. is set to release its financial results for Q1 2024 on May 15, 2024, followed by a conference call to discuss the results [1]. Company Overview - Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company with two FDA-approved products and a late-stage asset targeting pediatric progressive myopia [1][3]. - The company is focused on the commercialization of Mydcombi, an ophthalmic spray for mydriasis, and plans to launch clobetasol propionate ophthalmic suspension 0.05% for post-ocular surgery pain and inflammation later this summer [3]. Product Development - Eyenovia is advancing late-stage development of medications using its Optejet device, including MicroPine for myopia progression, in partnership with Arctic Vision in China and South Korea [4].